SCHEMBL4896658

SCHEMBL4896658

Brc1cccc(-c2cnccn2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 0.44
KDM4E B2RXH2 2/20 0.42
TP53 P04637 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
ALPL P05186 1/20 0.42
HSP90AA1 P07900 1/20 0.42
ALPI P09923 1/20 0.42
ALPG P10696 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
CCR1 P32246 1/20 0.42
HTT P42858 1/20 0.42
CCR5 P51681 1/20 0.42
CCR8 P51685 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PIM1 P11309 4/20 0.39
TGFBR1 P36897 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20169510 0.86 CCR1 (0.56) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL29661993 0.86 CCR1 (0.56) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL28768624 0.84 CCR1 (0.54) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL29539234 0.78 CCR1 (0.46) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL229994 0.78 CCR1 (0.46) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL353379 0.78 KDM4E (0.71) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL29946428 0.78 KDM4E (0.71) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL30485904 0.78 KDM4E (0.71) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL30528336 0.77 CCR1 (0.61) METAP2KDM4ETP53SMN1; SMN2LMNA
SCHEMBL13403463 0.77 ASIC3 (0.47) METAP2KDM4ETP53SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023072301-A1 PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF 正大天晴药业集团股份有限公司 2023-05-04 WO disclosed
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators ICAGEN, INC. (US) 2008-05-08 US disclosed
CN-1980923-A Polycyclic pyridines as potassium ion channel modulators ICAGEN INC (US) 2007-06-13 CN disclosed
EP-1737852-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS Icagen, Inc. (US) 2007-01-03 EP disclosed
WO-2005100349-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN, INC. (US) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators KCNJ2, KCNH2, KCNQ1 METAP2 4135/4885KDM4E 542/4885TP53 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.